Calliditas Therapeutics AB (publ)

NasdaqGS:CALT Stock Report

Market Cap: US$1.1b

Calliditas Therapeutics Past Earnings Performance

Past criteria checks 0/6

Calliditas Therapeutics's earnings have been declining at an average annual rate of -25.5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 61.3% per year.

Key information

-25.5%

Earnings growth rate

-20.2%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate61.3%
Return on equity-436.8%
Net Margin-40.0%
Next Earnings Update13 Aug 2024

Recent past performance updates

Recent updates

Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics

May 28

Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M

Aug 18

Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy

Jul 15

Calliditas submits nefecon marketing authorisation application to the EMA

May 28

Calliditas shares rise 10% as FDA grants priority review for Nefecon

Apr 28

Calliditas Therapeutics reports Q3 results

Nov 12

Revenue & Expenses Breakdown

How Calliditas Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:CALT Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 241,311-5251,163526
31 Dec 231,207-4661,061502
30 Sep 231,184-4511,040498
30 Jun 231,150-292968421
31 Mar 23944-393872428
31 Dec 22803-412775415
30 Sep 22405-628653413
30 Jun 22343-608562402
31 Mar 22279-576474381
31 Dec 21229-500390357
30 Sep 21199-452302331
30 Jun 210-600248304
31 Mar 210-501182277
31 Dec 201-433142241
30 Sep 2047-286102209
30 Jun 2047-19871190
31 Mar 20185-5471173
31 Dec 19185-3363150
30 Sep 19138-5447142
30 Jun 19138-3544120
31 Mar 190-1363399
31 Dec 180-1323199
30 Sep 180-1286465
30 Jun 180-1157441
31 Mar 180-1138131
31 Dec 170-87850
31 Dec 160-57560

Quality Earnings: CALT is currently unprofitable.

Growing Profit Margin: CALT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CALT is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.

Accelerating Growth: Unable to compare CALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CALT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).


Return on Equity

High ROE: CALT has a negative Return on Equity (-436.8%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.